Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
EDIT Inks Collaboration Deal to Develop Novel Gene Editing Therapies
Editas Medicine, Inc. EDIT announced that it has entered into a collaboration and nonexclusive license agreement with Canada-based privately held company Genevant Sciences to develop in vivo gene editing medicines.
Editas and Genevant team up to develop gene editing therapies
Editas is partnering its CRISPR platform with Genevant’s LNP technology to develop novel gene editing medicines in a deal worth $283m.
Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics
Under the terms of the agreement, Genevant has granted to
Editas
a nonexclusive worldwide license under certain Genevant LNP technology to exploit mRNA-
CRISPR
Cas12a-LNP products directed to two ...
Editas Medicine, Genevant Sciences enter collaboration and license agreement
Editas Medicine (EDIT) and Genevant Sciences announced that they have entered into a collaboration and nonexclusive license agreement to
BioPharma Dive
1d
Editas, changing course again, looks to partner lead CRISPR therapy
The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...
STAT
1d
Editas tacks again, steering from lead sickle cell treatment to new one
Editas, one of the oldest CRISPR-focused biotechs, is pivoting again — to a sickle cell treatment that requires editing a ...
1d
Buy Rating for Editas Medicine: Promising In Vivo CRISPR Platform and Strategic Growth Potential Amid Speculative Investment
Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jack Allen ...
GlobalData on MSN
19d
Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m
Amidst the long-running Cas9 patent battle, Editas Medicine has struck a deal to sell a portion of its future revenue stream ...
STAT
1d
‘Switchable’ CAR-T startup raises $112 million
AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies ...
precisionmedicineonline
16h
Editas Seeking Partner or Licensing Deal for Lead Sickle Cell, TDT Gene-Editing Treatment Candidate
The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.
1d
Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript
Editas Medicine, Inc. ( NASDAQ: EDIT) Strategic Update Conference Call October 22, 2024 8:00 AM ET ...
Future Market Insights
1d
CRISPR and Cas Gene Market Expected to Reach USD 32.9 Billion by 2033 New Heights with Projected Growth of 30.2% of CAGR
The global CRISPR and Cas Gene Market was valued at USD 1.8 billion in 2021. With an impressive projected growth rate of 30.2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback